Lluis Samaranch, PhD

TitleAssistant Researcher
InstitutionUniversity of California San Francisco
DepartmentNeurological Surgery
Address1855 Folsom Street
San Francisco CA 94103
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California San FranciscoPostdoctoral Fellow2014Neurological Surgery Dept.
    Center for Applied Medical ResearchPostdoctoral Fellow2010Neurogenetics Lab.
    University of NavarraPh.D (focus: Neuroscience)2006School of Medicine
    University of NavarraB.Sc (focus: Biochemistry)2001School of Science
    University of NavarraB.Sc (focus: Biomedical Science)2000School of Science
    Collapse Awards and Honors
    Spanish Ministry of Health2002Heath Research Fund Program Fellowship
    University of Navarra2004Applied Medical Research Foundation Fellowship
    Spanish Ministry of Science and Technology, co-financed by the European Social Fund.2007Torres Quevedo Fellowship
    National Niemann-Pick Disease Foundation2012Edward H. Schuchman Research Fellowship
    The National Agency for Quality Assessment and Accreditation of Spain2013Certification for the Assistant Professorship level. Area: GENETICS

    Collapse Overview 
    Collapse Overview
    Dr. Samaranch received his B.Sc. degree and PhD from the University of Navarra (Pamplona, Spain), studying biomarkers for early detection of Alzheimer-type dementia. During this time, he mastered many techniques in the fields of genetics, biochemistry, neuroimaging, and psychology.
    Dr. Samaranch performed his first post-doctoral training at the Applied Research Medical Center (Pamplona, Spain) where he worked on the genetic characterization of familial Parkinson’s disease through mapping new candidate genes and dissecting genetic risk factors of different genes involved as LRRK2, Parkin and PINK1. He continued his post-doctoral training at the UCSF Translational Neuroscience Research Laboratory, where he study the transport and expression levels of different serotypes of adeno-associated vectors carrying therapeutic transgenes after their delivery into the central nervous system.
    Currently, Dr. Samaranch is working on evaluation of brain and spinal cord distribution, axonal transport and cellular specificity of different serotypes of adeno-associated viral vectors after being injected in the central nervous system. His research focuses on brain parenchymal injections and cerebrospinal fluid delivery of therapeutic agents. Dr. Samaranch interests also include: i) the characterization of new capsid-engineered vectors as better tools for AAV-based gene therapy; ii) the deep understanding of the immunological consequences after adeno-associated viral vectors delivery into the central nervous system; and iii) the development of a therapeutic platform based on the CSF delivery of adeno-associated viral vectors for rare genetically inherited brain disease.

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Nagahara AH, Wilson BR, Ivasyk I, Kovacs I, Rawalji S, Bringas JR, Pivirotto PJ, Sebastian WS, Samaranch L, Bankiewicz KS, Tuszynski MH. MR-guided delivery of AAV2-BDNF into the entorhinal cortex of non-human primates. Gene Ther. 2018 Mar 13. PMID: 29535375.
      View in: PubMed
    2. Yazdan-Shahmorad A, Tian N, Kharazia V, Samaranch L, Kells A, Bringas J, He J, Bankiewicz K, Sabes PN. Widespread optogenetic expression in macaque cortex obtained with MR-guided, convection enhanced delivery (CED) of AAV vector to the thalamus. J Neurosci Methods. 2018 Jan 01; 293:347-358. PMID: 29042259.
      View in: PubMed
    3. Ciesielska A, Samaranch L, San Sebastian W, Dickson DW, Goldman S, Forsayeth J, Bankiewicz KS. Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial. PLoS One. 2017; 12(2):e0169965. PMID: 28166239.
      View in: PubMed
    4. Hadaczek P, Stanek L, Ciesielska A, Sudhakar V, Samaranch L, Pivirotto P, Bringas J, O'Riordan C, Mastis B, San Sebastian W, Forsayeth J, Cheng SH, Bankiewicz KS, Shihabuddin LS. Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington's disease. Mol Ther Methods Clin Dev. 2016; 3:16037. PMID: 27408903; PMCID: PMC4926858.
    5. Bankiewicz KS, Sudhakar V, Samaranch L, San Sebastian W, Bringas J, Forsayeth J. AAV viral vector delivery to the brain by shape-conforming MR-guided infusions. J Control Release. 2016 10 28; 240:434-442. PMID: 26924352.
      View in: PubMed
    6. Samaranch L, Bringas J, Pivirotto P, Sebastian WS, Forsayeth J, Bankiewicz K. Cerebellomedullary Cistern Delivery for AAV-Based Gene Therapy: A Technical Note for Nonhuman Primates. Hum Gene Ther Methods. 2016 Feb; 27(1):13-6. PMID: 26757202; PMCID: PMC4761826 [Available on 02/01/17].
    7. San Sebastian W, Kells AP, Bringas J, Samaranch L, Hadaczek P, Ciesielska A, Macayan M, Pivirotto PJ, Forsayeth J, Osborne S, Wright JF, Green F, Heller G, Bankiewicz KS. SAFETY AND TOLERABILITY OF MRI-GUIDED INFUSION OF AAV2-hAADC INTO THE MID-BRAIN OF NON-HUMAN PRIMATE. Mol Ther Methods Clin Dev. 2014 Oct 15; 3. PMID: 25541617.
      View in: PubMed
    8. Passini MA, Bu J, Richards AM, Treleaven CM, Sullivan JA, O'Riordan CR, Scaria A, Kells AP, Samaranch L, San Sebastian W, Federici T, Fiandaca MS, Boulis NM, Bankiewicz KS, Shihabuddin LS, Cheng SH. Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy. Hum Gene Ther. 2014 Jul; 25(7):619-30. PMID: 24617515.
      View in: PubMed
    9. Salegio EA, Streeter H, Dube N, Hadaczek P, Samaranch L, Kells AP, San Sebastian W, Zhai Y, Bringas J, Xu T, Forsayeth J, Bankiewicz KS. Distribution of nanoparticles throughout the cerebral cortex of rodents and non-human primates: Implications for gene and drug therapy. Front Neuroanat. 2014; 8:9. PMID: 24672434; PMCID: PMC3956368.
    10. Samaranch L, Sebastian WS, Kells AP, Salegio EA, Heller G, Bringas JR, Pivirotto P, DeArmond S, Forsayeth J, Bankiewicz KS. AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. Mol Ther. 2014 Feb; 22(2):329-337. PMID: 24419081; PMCID: PMC3918916.
    11. San Sebastian W, Samaranch L, Kells AP, Forsayeth J, Bankiewicz KS. Gene therapy for misfolding protein diseases of the central nervous system. Neurotherapeutics. 2013 Jul; 10(3):498-510. PMID: 23700209; PMCID: PMC3701766.
    12. Samaranch L, Salegio EA, San Sebastian W, Kells AP, Bringas JR, Forsayeth J, Bankiewicz KS. Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum Gene Ther. 2013 May; 24(5):526-32. PMID: 23517473; PMCID: PMC3655626.
    13. de Mena L, Samaranch L, Coto E, Cardo LF, Ribacoba R, Lorenzo-Betancor O, Pastor P, Wang L, Irigoyen J, Mata IF, Díaz M, Moris G, Menéndez M, Corao AI, Lorenzo E, Alvarez V. Mutational screening of PARKIN identified a 3' UTR variant (rs62637702) associated with Parkinson's disease. J Mol Neurosci. 2013 Jun; 50(2):264-9. PMID: 23275044.
      View in: PubMed
    14. Salegio EA, Samaranch L, Jenkins RW, Clarke CJ, Lamarre C, Beyer J, Kells AP, Bringas J, Sebastian WS, Richardson RM, Rosenbluth KH, Hannun YA, Bankiewicz KS, Forsayeth J. Safety study of adeno-associated virus serotype 2-mediated human acid sphingomyelinase expression in the nonhuman primate brain. Hum Gene Ther. 2012 Aug; 23(8):891-902. PMID: 22574943; PMCID: PMC3413900.
    15. García-Martín E, Martínez C, Alonso-Navarro H, Benito-León J, Lorenzo-Betancor O, Pastor P, López-Alburquerque T, Samaranch L, Lorenzo E, Agúndez JA, Jiménez-Jiménez FJ. H1-MAPT and the risk for familial essential tremor. PLoS One. 2012; 7(7):e41581. PMID: 22911817; PMCID: PMC3402423.
    16. Botta-Orfila T, Ezquerra M, Pastor P, Fernández-Santiago R, Pont-Sunyer C, Compta Y, Lorenzo-Betancor O, Samaranch L, Martí MJ, Valldeoriola F, Calopa M, Fernández M, Aguilar M, de Fabregas O, Hernández-Vara J, Tolosa E. Age at onset in LRRK2-associated PD is modified by SNCA variants. J Mol Neurosci. 2012 Sep; 48(1):245-7. PMID: 22669510.
      View in: PubMed
    17. Samaranch L, Salegio EA, San Sebastian W, Kells AP, Foust KD, Bringas JR, Lamarre C, Forsayeth J, Kaspar BK, Bankiewicz KS. Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther. 2012 Apr; 23(4):382-9. PMID: 22201473; PMCID: PMC3327605.
    18. Salegio EA, Samaranch L, Kells AP, Mittermeyer G, San Sebastian W, Zhou S, Beyer J, Forsayeth J, Bankiewicz KS. Axonal transport of adeno-associated viral vectors is serotype-dependent. Gene Ther. 2013 Mar; 20(3):348-52. PMID: 22418061; PMCID: PMC3381869.
    19. Cardo LF, Coto E, de Mena L, Ribacoba R, Lorenzo-Betancor O, Pastor P, Samaranch L, Mata IF, Díaz M, Moris G, Menéndez M, Corao AI, Alvarez V. A search for SNCA 3' UTR variants identified SNP rs356165 as a determinant of disease risk and onset age in Parkinson's disease. J Mol Neurosci. 2012 Jul; 47(3):425-30. PMID: 22076805.
      View in: PubMed
    20. Lorenzo-Betancor O, Samaranch L, Ezquerra M, Tolosa E, Lorenzo E, Irigoyen J, Gaig C, Pastor MA, Soto-Ortolaza AI, Ross OA, Rodríguez-Oroz MC, Valldeoriola F, Martí MJ, Luquin MR, Perez-Tur J, Burguera JA, Obeso JA, Pastor P. LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation. Mov Disord. 2012 Jan; 27(1):146-51. PMID: 22038903.
      View in: PubMed
    21. Salegio EA, Samaranch L, Kells AP, Forsayeth J, Bankiewicz K. Guided delivery of adeno-associated viral vectors into the primate brain. Adv Drug Deliv Rev. 2012 May 15; 64(7):598-604. PMID: 22036906; PMCID: PMC3279613.
    22. Coria F, Gimenez-Garcia M, Samaranch L, Mora FJ, Sampol-Bas C, Pastor P. Nigrostriatal dopaminergic function in subjects with isolated action tremor. Parkinsonism Relat Disord. 2012 Jan; 18(1):49-53. PMID: 21917500.
      View in: PubMed
    23. Cervantes S, Samaranch L, Vidal-Taboada JM, Lamet I, Bullido MJ, Frank-García A, Coria F, Lleó A, Clarimón J, Lorenzo E, Alonso E, Sánchez-Juan P, Rodríguez-Rodríguez E, Combarros O, Rosich M, Vilella E, Pastor P. Genetic variation in APOE cluster region and Alzheimer's disease risk. Neurobiol Aging. 2011 Nov; 32(11):2107.e7-17. PMID: 21752496.
      View in: PubMed
    24. Mata IF, Yearout D, Alvarez V, Coto E, de Mena L, Ribacoba R, Lorenzo-Betancor O, Samaranch L, Pastor P, Cervantes S, Infante J, Garcia-Gorostiaga I, Sierra M, Combarros O, Snapinn KW, Edwards KL, Zabetian CP. Replication of MAPT and SNCA, but not PARK16-18, as susceptibility genes for Parkinson's disease. Mov Disord. 2011 Apr; 26(5):819-23. PMID: 21425343; PMCID: PMC3082603.
    25. Lorenzo-Betancor O, Samaranch L, García-Martín E, Cervantes S, Agúndez JA, Jiménez-Jiménez FJ, Alonso-Navarro H, Luengo A, Coria F, Lorenzo E, Irigoyen J, Pastor P. LINGO1 gene analysis in Parkinson's disease phenotypes. Mov Disord. 2011 Mar; 26(4):722-7. PMID: 21506150.
      View in: PubMed
    26. Botta-Orfila T, Ezquerra M, Ríos J, Fernández-Santiago R, Cervantes S, Samaranch L, Pastor P, Martí MJ, Muñoz E, Valldeoriola F, Aguilar M, Calopa M, Hernández-Vara J, Tolosa E. Lack of interaction of SNCA and MAPT genotypes in Parkinson's disease. Eur J Neurol. 2011 Mar; 18(3):e32. PMID: 21054681.
      View in: PubMed
    27. de Mena L, Coto E, Cardo LF, Díaz M, Blázquez M, Ribacoba R, Salvador C, Pastor P, Samaranch L, Moris G, Menéndez M, Corao AI, Alvarez V. Analysis of the Micro-RNA-133 and PITX3 genes in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet. 2010 Sep; 153B(6):1234-9. PMID: 20468068.
      View in: PubMed
    28. Samaranch L, Lorenzo-Betancor O, Arbelo JM, Ferrer I, Lorenzo E, Irigoyen J, Pastor MA, Marrero C, Isla C, Herrera-Henriquez J, Pastor P. PINK1-linked parkinsonism is associated with Lewy body pathology. Brain. 2010 Apr; 133(Pt 4):1128-42. PMID: 20356854.
      View in: PubMed
    29. Samaranch L, Cervantes S, Barabash A, Alonso A, Cabranes JA, Lamet I, Ancín I, Lorenzo E, Martínez-Lage P, Marcos A, Clarimón J, Alcolea D, Lleó A, Blesa R, Gómez-Isla T, Pastor P. The effect of MAPT H1 and APOE e4 on transition from mild cognitive impairment to dementia. J Alzheimers Dis. 2010; 22(4):1065-71. PMID: 20930301.
      View in: PubMed
    30. Samaranch L, Lorenzo E, Pastor MA, Riverol M, Luquin MR, Rodríguez-Oroz MC, Obeso JA, Pastor P. Analysis of the GIGYF2 gene in familial and sporadic Parkinson disease in the Spanish population. Eur J Neurol. 2010 Feb; 17(2):321-5. PMID: 19845746.
      View in: PubMed
    31. Rodriguez-Oroz MC, Lage PM, Sanchez-Mut J, Lamet I, Pagonabarraga J, Toledo JB, García-Garcia D, Clavero P, Samaranch L, Irurzun C, Matsubara JM, Irigoien J, Bescos E, Kulisevsky J, Pérez-Tur J, Obeso JA. Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study. Mov Disord. 2009 Jul 30; 24(10):1437-44. PMID: 19452554.
      View in: PubMed
    32. Riverol M, Samaranch L, Pascual B, Pastor P, Irigoyen J, Pastor MA, de Castro P, Masdeu JC. Forceps minor region signal abnormality "ears of the lynx": an early MRI finding in spastic paraparesis with thin corpus callosum and mutations in the spatacsin gene (SPG11) on chromosome 15. J Neuroimaging. 2009 Jan; 19(1):52-60. PMID: 19040626.
      View in: PubMed
    33. Cruchaga C, Fernández-Seara MA, Seijo-Martínez M, Samaranch L, Lorenzo E, Hinrichs A, Irigoyen J, Maestro C, Prieto E, Martí-Climent JM, Arbizu J, Pastor MA, Pastor P. Cortical atrophy and language network reorganization associated with a novel progranulin mutation. Cereb Cortex. 2009 Aug; 19(8):1751-60. PMID: 19020205.
      View in: PubMed
    34. Guerreiro RJ, Baquero M, Blesa R, Boada M, Brás JM, Bullido MJ, Calado A, Crook R, Ferreira C, Frank A, Gómez-Isla T, Hernández I, Lleó A, Machado A, Martínez-Lage P, Masdeu J, Molina-Porcel L, Molinuevo JL, Pastor P, Pérez-Tur J, Relvas R, Oliveira CR, Ribeiro MH, Rogaeva E, Sa A, Samaranch L, Sánchez-Valle R, Santana I, Tàrraga L, Valdivieso F, Singleton A, Hardy J, Clarimón J. Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiol Aging. 2010 May; 31(5):725-31. PMID: 18667258.
      View in: PubMed
    35. Samaranch L, Riverol M, Masdeu JC, Lorenzo E, Vidal-Taboada JM, Irigoyen J, Pastor MA, de Castro P, Pastor P. SPG11 compound mutations in spastic paraparesis with thin corpus callosum. Neurology. 2008 Jul 29; 71(5):332-6. PMID: 18663179.
      View in: PubMed
    36. Duque B, Sepulcre J, Bejarano B, Samaranch L, Pastor P, Villoslada P. Memory decline evolves independently of disease activity in MS. Mult Scler. 2008 Aug; 14(7):947-53. PMID: 18573817.
      View in: PubMed
    37. Blázquez L, De Juan D, Ruiz-Martínez J, Emparanza JI, Sáenz A, Otaegui D, Sistiaga A, Martínez-Lage P, Lamet I, Samaranch L, Buiza C, Etxeberria I, Arriola E, Cuadrado E, Urdaneta E, Yanguas J, López de Munain A. Genes related to iron metabolism and susceptibility to Alzheimer's disease in Basque population. Neurobiol Aging. 2007 Dec; 28(12):1941-3. PMID: 17011669.
      View in: PubMed
    38. Ribé EM, Pérez M, Puig B, Gich I, Lim F, Cuadrado M, Sesma T, Catena S, Sánchez B, Nieto M, Gómez-Ramos P, Morán MA, Cabodevilla F, Samaranch L, Ortiz L, Pérez A, Ferrer I, Avila J, Gómez-Isla T. Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol Dis. 2005 Dec; 20(3):814-22. PMID: 16125396.
      View in: PubMed